Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer von Bitting, Rhonda L, Armstrong, Andrew J

Volltext

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial von Penson, David F, Armstrong, Andrew J, Concepcion, Raoul, Agarwal, Neeraj, Olsson, Carl, Karsh, Lawrence, Dunshee, Curtis, Wang, Fong, Wu, Kenneth, Krivoshik, Andrew, Phung, De, Higano, Celestia S

Volltext

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study von Armstrong, Andrew J, Halabi, Susan, Luo, Jun, Nanus, David M, Giannakakou, Paraskevi, Szmulewitz, Russell Z, Danila, Daniel C, Healy, Patrick, Anand, Monika, Rothwell, Colin J, Rasmussen, Julia, Thornburg, Blair, Berry, William R, Wilder, Rhonda S, Lu, Changxue, Chen, Yan, Silberstein, John L, Kemeny, Gabor, Galletti, Giuseppe, Somarelli, Jason A, Gupta, Santosh, Gregory, Simon G, Scher, Howard I, Dittamore, Ryan, Tagawa, Scott T, Antonarakis, Emmanuel S, George, Daniel J

Volltext

Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity von Shuch, Brian, Amin, Ali, Armstrong, Andrew J, Eble, John N, Ficarra, Vincenzo, Lopez-Beltran, Antonio, Martignoni, Guido, Rini, Brian I, Kutikov, Alexander

Volltext

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial von Armstrong, Andrew J, Dr, Halabi, Susan, Prof, Eisen, Tim, Prof, Broderick, Samuel, MS, Stadler, Walter M, Prof, Jones, Robert J, Prof, Garcia, Jorge A, MD, Vaishampayan, Ulka N, Prof, Picus, Joel, Prof, Hawkins, Robert E, Prof, Hainsworth, John D, Prof, Kollmannsberger, Christian K, Prof, Logan, Theodore F, Prof, Puzanov, Igor, MD, Pickering, Lisa M, MD, Ryan, Christopher W, MD, Protheroe, Andrew, MD, Lusk, Christine M, MPH, Oberg, Sadie, BS, George, Daniel J, Prof

Volltext

Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin von ARMSTRONG, Andrew J, GEORGE, Daniel J, HALABI, Susan

Volltext

RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis von Wang, Mu-En, Chen, Jiaqi, Lu, Yi, Bawcom, Alyssa R, Wu, Jinjin, Ou, Jianhong, Asara, John M, Armstrong, Andrew J, Wang, Qianben, Li, Lei, Wang, Yuzhuo, Huang, Jiaoti, Chen, Ming

Volltext

Novel therapies are changing treatment paradigms in metastatic prostate cancer von Powers, Eric, Karachaliou, Georgia Sofia, Kao, Chester, Harrison, Michael R, Hoimes, Christopher J, George, Daniel J, Armstrong, Andrew J, Zhang, Tian

Volltext

Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells von Stoyanova, Tanya, Cooper, Aaron R., Drake, Justin M., Liu, Xian, Armstrong, Andrew J., Pienta, Kenneth J., Zhang, Hong, Kohn, Donald B., Huang, Jiaoti, Witte, Owen N., Goldstein, Andrew S.

Volltext

Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer von ARMSTRONG, Andrew J, GARRETT-MAYER, Elizabeth, DE WIT, Ronald, TANNOCK, Ian, EISENBERGER, Mario

Volltext

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial von Araujo, John C, Dr, Trudel, Géralyn C, PhD, Saad, Fred, Prof, Armstrong, Andrew J, MD, Yu, Evan Y, MD, Bellmunt, Joaquim, MD, Wilding, George, Prof, McCaffrey, John, Prof, Serrano, Sergio V, MD, Matveev, Vsevolod B, Prof, Efstathiou, Eleni, MD, Oudard, Stephane, Prof, Morris, Michael J, MD, Sizer, Bruce, MBChB, Goebell, Peter J, MD, Heidenreich, Axel, Prof, de Bono, Johann S, Prof, Begbie, Stephen, MBBS, Hong, Jun H, MD, Richardet, Eduardo, MD, Gallardo, Enrique, MD, Paliwal, Prashni, PhD, Durham, Susan, BA, Cheng, Shinta, MD, Logothetis, Christopher J, Prof

Volltext

Clinical utility of non-EpCAM based circulating tumor cell assays von Austin, R. Garland, Huang, Tony Jun, Wu, Mengxi, Armstrong, Andrew J., Zhang, Tian

Volltext

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond von Zhu, Jason, Armstrong, Andrew J, Friedlander, Terence W, Kim, Won, Pal, Sumanta K, George, Daniel J, Zhang, Tian

Volltext

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer von PILI, Roberto, HÄGGMAN, Michael, STADLER, Walter M, GINGRICH, Jeffrey R, ASSIKIS, Vasileios J, BJÖRK, Anders, NORDLE, Orjan, FORSBERG, Goran, CARDUCCI, Michael A, ARMSTRONG, Andrew J

Volltext

Docetaxel for advanced prostate cancer: how early to start? von Armstrong, Andrew J

Volltext

Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2 von Somarelli, Jason A., Shetler, Samantha, Jolly, Mohit K., Wang, Xueyang, Bartholf Dewitt, Suzanne, Hish, Alexander J., Gilja, Shivee, Eward, William C., Ware, Kathryn E., Levine, Herbert, Armstrong, Andrew J., Garcia-Blanco, Mariano A.

Volltext

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients von Knutson, Todd P., Luo, Bin, Kobilka, Anna, Lyman, Jacqueline, Guo, Siyuan, Munro, Sarah A., Li, Yingming, Heer, Rakesh, Gaughan, Luke, Morris, Michael J., Beltran, Himisha, Ryan, Charles J., Antonarakis, Emmanuel S., Armstrong, Andrew J., Halabi, Susan, Dehm, Scott M.

Volltext

A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis von ARMSTRONG, Andrew J, GARRETT-MAYER, Elizabeth S, OU YANG, Yi-Chun, DE WIT, Ronald, TANNOCK, Ian F, EISENBERGER, Mario

Volltext

Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy von HALABI, Susan, ARMSTRONG, Andrew J, SARTOR, Oliver, DE BONO, Johann, KAPLAN, Ellen, LIN, Chen-Yen, SOLOMON, Nicole C, SMALL, Eric J

Volltext

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types von Brown, Landon C, Tucker, Matthew D, Sedhom, Ramy, Schwartz, Eric B, Zhu, Jason, Kao, Chester, Labriola, Matthew K, Gupta, Rajan T, Marin, Daniele, Wu, Yuan, Gupta, Santosh, Zhang, Tian, Harrison, Michael R, George, Daniel J, Alva, Ajjai, Antonarakis, Emmanuel S, Armstrong, Andrew J

Volltext